By vgreene, 17 June, 2019 Consider also these emerging biomarkers to identify novel therapies for metastatic NSCLC pts:1
By vgreene, 17 June, 2019 Consider also these emerging biomarkers to identify novel therapies for metastatic NSCLC pts:
By vgreene, 17 June, 2019 Tumor mutational burden (TMB) - may be helpful in selecting pts for immunotherapy but no consensus on how to measure it
By vgreene, 17 June, 2019 ERBB2 (HER2) molecular testing: Not indicated as routine stand-alone assay outside the context of a clinical trial; perform as part of a larger testing panel either initially or when routine EFGR, ALK, BRAF, and ROS1 testing is negative2
By vgreene, 17 June, 2019 RET molecular testing1,2 Not recommended as a routine stand-alone assay outside of context of clinical trial, but appropriate to include RET as part of larger testing panels performed either initially or when routine EGFR, ALK, BRAF, and ROS1 testing is n
By vgreene, 17 June, 2019 High-level MET amplification of MET exon 14 skipping mutation: Not indicated as routine stand-alone assay outside the context of a clinical trial; perform as part of a larger testing panel either initially or when routine EFGR, ALK, BRAF, and ROS1 testin
By vgreene, 17 June, 2019 At a minimum, consider the following molecular testing (which should be conducted as part of broader molecular profiling):1